Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDKN1A
REST API REST API
Homo sapiens
CDKN1A is differentially expressed in 341 experiments: 118 organism parts: bone marrow, cerebellum, ... (116 more);, 167 disease states: normal, glioblastoma, ... (165 more);, 113 cell types 433 cell lines 56 compound treatments and 68 other conditions.
Synonyms p21Cip1/Waf1, p21CIP1, CAP20, CIP1, P21, WAF1, CDKN1, SDI1
Orthologs CDKN1A (Gallus gallus)   Cdkn1a (Mus musculus)   A5PKM2_BOVIN (Bos taurus)   cdkn1a (Danio rerio)   Cdkn1a (Rattus norvegicus)   cdkn1a (Xenopus laevis)   Q683K8_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, cyclin-dependent protein kinase activity, cytosol, negative regulation of cell growth, phosphorylation, protein binding, cytoplasm, negative regulation of cell proliferation, response to toxin, mitotic cell cycle, regulation of cyclin-dependent protein kinase activity, negative regulation of apoptosis, cell cycle arrest, metal ion binding, G1 phase of mitotic cell cycle, regulation of mitotic cell cycle, cell cycle, Ras protein signal transduction, regulation of cell cycle, G1/S transition of mitotic cell cycle, nucleus, G2/M transition of mitotic cell cycle, kinase activity, cyclin binding, response to drug, positive regulation of programmed cell death, nucleoplasm, cell cycle checkpoint, response to DNA damage stimulus, S phase of mitotic cell cycle, cyclin-dependent protein kinase inhibitor activity, negative regulation of gene expression, negative regulation of cyclin-dependent protein kinase activity, response to corticosterone stimulus, DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest, positive regulation of B cell proliferation, response to organic nitrogen, regulation of protein import into nucleus, translocation, protein kinase inhibitor activity, induction of apoptosis by intracellular signals, positive regulation of anti-apoptosis, cellular response to extracellular stimulus, organ regeneration, PCNA-p21 complex, positive regulation of fibroblast proliferation, negative regulation of phosphorylation, response to organic substance, response to hyperoxia, cyclin-dependent protein kinase holoenzyme complex, response to glucocorticoid stimulus, cyclin-dependent protein kinase activating kinase activity, response to arsenic-containing substance, regulation of DNA biosynthetic process, response to organic cyclic compound, positive regulation of reactive oxygen species metabolic process, cellular senescence, cellular response to ionizing radiation, stress-induced premature senescence
InterPro Term CDI
UniProt Accession Q6FI05, P38936
Search EB-eye ENSG00000124762
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7224, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (45 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-GEOD-2509, E-MTAB-37, E-GEOD-18005
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
HepG2
3
E-MTAB-37, E-GEOD-7307, E-GEOD-21154
HCC2157
2
E-MTAB-37, E-MTAB-62
K562
2
E-MTAB-37, E-GEOD-24147
MCF7
2
E-GEOD-5258, E-MTAB-37
427 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-MEXP-750, ... (59 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3204, E-GEOD-26672, E-GEOD-3920
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
macrophage
2
3
E-GEOD-5099, E-GEOD-3982, E-GEOD-8286, E-GEOD-360, E-GEOD-22373 ... (5 experiments)
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
107 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-MEXP-1121, E-TABM-15, ... (63 experiments)

Factor Value U/D Experiments
uterine fibroid
2
E-GEOD-2724, E-MTAB-62
breast cancer
2
E-MTAB-62, E-GEOD-22544
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
chronic myelogenous leukemia
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
obesity
2
E-MTAB-62, E-GEOD-2508
161 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (37 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-941, E-MEXP-1335
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
NaOH
1
E-MEXP-2590
rapamycin
1
E-GEOD-5824
insulin
1
E-GEOD-22309
1,2,4-benzenetriol
1
E-GEOD-7664
50 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
86 years
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-GEOD-22148, E-TABM-147, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-4025, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-GEOD-2152, E-GEOD-17476, E-GEOD-22593, E-GEOD-18005, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-TABM-440, E-GEOD-837, ... (13 experiments)

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-16194

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-TABM-740, E-MEXP-1290, ... (23 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-GEOD-6802

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1493, E-GEOD-21750, E-GEOD-5824, E-GEOD-1657, E-GEOD-17636, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-20295

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-GEOD-2748

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Vehicle
studied in E-GEOD-5258

Processing time: 0.386 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM